Oculis to Present at Upcoming February Investor Conferences
Oculis Holding AG (Nasdaq: OCS) announced its participation in upcoming investor conferences, including the Stifel Biotech Executive Summit and BioCapital Europe 2024. The company's CEO and CFO will be presenting at these events, providing an opportunity for interested investors to engage with Oculis' management.
01/29/2024 - 06:30 AM
ZUG, Switzerland and BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis’ management will be attending and presenting at the following upcoming investor conferences:
Stifel Biotech Executive Summit
BioCapital Europe 2024
The Company will be available for one-on-one meetings during the conferences. Interested investors should contact their respective representative at the sponsoring institutions to request meetings.
About Oculis
Oculis (Nasdaq: OCS) is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis’s highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2 development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the US, Oculis’ goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.
For more information, please visit: www.oculis.com
Oculis Contacts sylvia.cheung@oculis.com
Investor & Media Relations cdavis@lifesciadvisors.com
When is Oculis Holding AG presenting at the Stifel Biotech Executive Summit?
Oculis Holding AG will be presenting at the Stifel Biotech Executive Summit on February 7, 2024, at 7:30 am MT (Mountain Time).
Where will the BioCapital Europe 2024 conference take place?
The BioCapital Europe 2024 conference will take place at Hotel Sofitel Legend The Grand Amsterdam, Amsterdam, Netherlands.
How can interested investors schedule meetings with Oculis' management during the conferences?
Interested investors should contact their respective representative at the sponsoring institutions to request meetings with Oculis' management.
